Serious adverse events: hospitalisation · dialysis vascular access outcomes in AVG patients with ESKD
It is very uncertain whether omega‐3 fatty acids changes serious adverse events: hospitalisation compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects (other reported events) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Alopecia, skin toxicity, hot flush, drowsiness, sneezing, hiccupping, dizziness and fatigue reported narratively or only for the amifostine group; insufficient evidence of a difference
Studies not reported
GRADE not reported
Adverse events Number of adverse events · patients with essential tremor
It is very uncertain whether zonisamide changes adverse events Number of adverse events compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects (other reported events) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
No evidence of a difference for any other adverse event (nausea, vomiting, chilling, headache, lacrimation, dysphasia, weakness, nervousness, rhinitis, blurred vision, urinary frequency, dizziness, palpitation, skin…
Studies not reported
GRADE not reported
All topical NSAIDs Local adverse events · adults with strains, sprains, or muscle pull
1 finding from 1 review
Intervention not reported
Severe adverse events11 · Pregnant women (parity 2+)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events during treatment period · symptomatic people with COVID‐19
It is very uncertain whether fluvoxamine plus standard care changes any adverse events (during study period) compared with placebo plus standard care (very low certainty).
1 finding from 1 review
Adverse events ‐ malignancy at 36 months · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether calcineurin inhibitors ± steroids changes adverse events ‐ malignancy at 36 months compared with placebo/no treatment/supportive treatment/steroids (very low certainty).
1 finding from 1 review
Participants with serious adverse events · people who have been exposed to SARS‐CoV‐2
1 finding from 1 review
Participants with serious adverse events · adults with mild to severe COVID‐19
Hydroxychloroquine (HCQ) showed no clear difference in participants with serious adverse events compared with standard care or placebo (low certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · hospitalised individuals with COVID‐19 (moderate to severe disease)
Bamlanivimab showed no clear difference in adverse events: grades 3 and 4 by day 30 compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with TTR‐FAP
It is very uncertain whether diflunisal changes number of dropouts due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with TTR‐FAP
Patisiran may leads to lower number of dropouts due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with TTR‐FAP
Inotersen may leads to higher number of dropouts due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with early‐stage TTR‐FAP
It is very uncertain whether tafamidis changes number of dropouts due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events or adverse events · people with asthma
The review found no eligible studies for this question.
1 finding from 1 review
Statins for asthma 2020 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Adverse events attributable to treatment · children with SMA type I
1 finding from 1 review
Adverse events: osteonecrosis of the jaw · men with advanced prostate cancer
It is very uncertain whether bisphosphonates changes adverse events: osteonecrosis of the jaw compared with placebo/no treatment (very low certainty).
1 finding from 1 review
Proportion of people with adverse events · people with primary sclerosing cholangitis
It is very uncertain whether ursodeoxycholic acid changes proportion of people with adverse events compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events (Panaccione 2010) · induction of remission in Crohn's disease
Briakinumab showed no clear difference in serious adverse events (Panaccione 2010) compared with placebo (low certainty).
1 finding from 1 review